Avenacy, a specialty pharmaceutical company focused on critical injectable medications, announced today the launch of five injectable antibiotic products in the U.S. market. This expansion represents a significant addition to the company's growing portfolio of essential generic medications.
The newly launched products include Ampicillin for Injection, Ampicillin and Sulbactam for Injection, Nafcillin for Injection, Penicillin G Potassium for Injection, and Piperacillin and Tazobactam for Injection. Combined, these products generated approximately $175 million in U.S. sales for the twelve months ending September 30, 2024.
"The launch of these five antibiotic products further strengthens Avenacy's foundational portfolio of high-usage, critical injectable products," said Jeff Yordon, Co-Founder and CEO of Avenacy. "I am proud of how swiftly this team has worked to successfully bring 20 important medications to the U.S. market."
Strategic Market Expansion
With this launch, Avenacy has now introduced 20 products in less than 14 months since its inception in October 2023. The company continues to make progress toward its target of offering more than 25 products by the end of 2025.
The addition of these antibiotics allows Avenacy to deepen its commercial presence in both hospital and long-term/home health settings. According to Yordon, this growing antibiotic portfolio positions the company to drive continued market expansion supporting its long-term strategic objectives.
Enhanced Safety Features
In alignment with Avenacy's mission to prioritize patient safety and streamline care, all five antibiotic products feature the company's differentiated packaging and labeling designed to support accurate medication selection—a critical factor in preventing medication errors in clinical settings.
The company will begin shipping all five antibiotics to wholesale partners next week, supported by a global network of development and contract manufacturing partners that have undergone successful FDA inspections based on current Good Manufacturing Practice (cGMP) standards.
Product Details and Clinical Applications
The newly launched products address a range of serious bacterial infections:
Ampicillin for Injection, USP (therapeutic equivalent to Omnipen-N®) is indicated for respiratory tract infections, bacterial meningitis, septicemia, endocarditis, urinary tract infections, and gastrointestinal infections caused by susceptible organisms. U.S. sales were approximately $3 million for the twelve months ending September 2024.
Ampicillin and Sulbactam for Injection, USP (therapeutic equivalent to Unasyn®) is indicated for skin and skin structure infections, intra-abdominal infections, and gynecological infections caused by beta-lactamase producing bacterial strains. This product had U.S. sales of approximately $44 million for the twelve months ending September 2024.
Nafcillin for Injection, USP (therapeutic equivalent to Nallpen®) is indicated for treating infections caused by penicillinase-producing staphylococci that have demonstrated susceptibility to the drug. U.S. sales were approximately $5 million for the twelve months ending September 2024.
Penicillin G Potassium for Injection, USP (therapeutic equivalent to Pfizerpen-G®) is indicated for serious infections caused by susceptible strains of designated microorganisms. This product had U.S. sales of approximately $13 million for the twelve months ending September 2024.
Piperacillin and Tazobactam for Injection, USP (therapeutic equivalent to Zosyn®) is indicated for intra-abdominal infections, nosocomial pneumonia, skin and skin structure infections, female pelvic infections, and community-acquired pneumonia. With U.S. sales of approximately $110 million for the twelve months ending September 2024, this represents the largest market opportunity among the newly launched products.
Industry Context and Supply Chain Resilience
The launch comes at a time when the U.S. healthcare system continues to face challenges with drug shortages, particularly for injectable medications. By expanding its portfolio of generic injectables, Avenacy aims to contribute to a more resilient pharmaceutical supply chain.
"With an experienced team, commitment to quality and reliability, and product offerings intended to facilitate safe and efficient patient care, Avenacy strives to be a trusted partner for essential medications," the company stated in its announcement.
Company Background
Avenacy is a U.S.-based specialty pharmaceutical company headquartered in Schaumburg, Illinois. Founded in 2023, the company focuses on supplying critical injectable medications used to treat patients across various healthcare settings, from acute care hospitals to outpatient clinics and physician offices.
The company employs a rigorous selection process to build a pipeline of high-quality FDA-approved injectable products designed to meet the needs of today's dynamic drug supply chain. Avenacy will be showcasing its portfolio and discussing its 2025 growth strategy at DCAT Week 2025 in New York City from March 17-20.
